CERE News and Press, Ceres Inc. From 02/15/22

In healthy volunteers, both the 7.5 mg and 25 mg twice-daily doses of darigabat demonstrated a clinically meaningful and statistically significant improvement in the Panic Symptoms List score after eight days of dosing compared with placebo Darigabat was generally well-tolerated...

Emraclidine now the international nonproprietary name (INN) for CVL-231, an M4-selective positive allosteric modulator in development for schizophrenia Company expects to initiate Phase 2 program for emraclidine in schizophrenia by the middle of 2022, with data expected in the f...

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a global company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that Chairperson and Chief Executive Officer Tony Coles, M.D., will present at the...

CAMBRIDGE, Mass. and SAN FRANCISCO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, and Herophilus, a leading biotechnology company developing neurotherapeutics to cur...

Although the Healthcare sector is having a positive year in absolute terms, that isn't the case in relative terms. Biotech stocks are having a difficult year, in spite of many of those trading at dirt-cheap valuations that don't even reflect the cash they have in-hand. It's very l...

The following slide deck was published by Cerevel Therapeutics Holdings, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Cerevel Therapeutics Holdings, Inc. 2021 Q3 - Results - Earnings Call Presentation

Cerevel Therapeutics Holdings, Inc. (CERE) Q3 2021 Results Earnings Conference Call November 10, 2021, 08:00 AM ET Company Participants Matthew Calistri - Vice President of Investor Relations Tony Coles - Chairperson & Chief Executive Officer Ray Sanchez - Chief Medical Officer John Renge...

Phase 1 data for darigabat in acute anxiety now expected by the end of Q1 2022 Submissions of additional PK/PD data for CVL-231 in schizophrenia accepted for presentation at the Annual Meeting of the American College of Neuropsychopharmacology Conference call and webcast...

Shares of Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) traded at a new 52-week high today of $46.12. This new high was reached on above average trading volume as 9 million shares traded hands, while the average 30-day volume is approximately 363,000 shares. Cerevel Therapeutics Holdi...

Shares of Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) traded today at $43.31, eclipsing its 52-week high. Approximately 9 million shares have changed hands today, as compared to an average 30-day volume of 417,000 shares. Cerevel Therapeutics Holdings Inc is dedicated to unraveling ...